Organogenesis Holdings Inc. (NASDAQ:ORGO) Insider Purchases $26,975.78 in Stock

Organogenesis Holdings Inc. (NASDAQ:ORGO - Get Free Report) insider Lori Freedman purchased 9,022 shares of the firm's stock in a transaction dated Friday, June 6th. The shares were bought at an average cost of $2.99 per share, with a total value of $26,975.78. Following the purchase, the insider now directly owns 846,459 shares of the company's stock, valued at approximately $2,530,912.41. This represents a 1.08% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink.

Lori Freedman also recently made the following trade(s):

• On Thursday, June 5th, Lori Freedman purchased 142,379 shares of Organogenesis stock. The shares were bought at an average cost of $2.91 per share, with a total value of $414,322.89.
• On Wednesday, June 4th, Lori Freedman acquired 100,863 shares of Organogenesis stock. The shares were acquired at an average cost of $2.82 per share, for a total transaction of $284,433.66.

Organogenesis Stock Performance

Shares of ORGO traded up $0.15 during trading hours on Friday, reaching $3.03. 991,674 shares of the company traded hands, compared to its average volume of 1,145,660. The stock has a market capitalization of $384.37 million, a P/E ratio of -50.50 and a beta of 1.85. The company has a quick ratio of 2.74, a current ratio of 3.09 and a debt-to-equity ratio of 0.21. Organogenesis Holdings Inc. has a 12-month low of $2.28 and a 12-month high of $6.71. The business has a fifty day moving average price of $3.85 and a 200-day moving average price of $3.86.

Organogenesis (NASDAQ:ORGO - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.04 by ($0.17). The business had revenue of $86.69 million for the quarter, compared to analyst estimates of $90.77 million. Organogenesis had a negative net margin of 1.62% and a negative return on equity of 2.69%. Equities analysts anticipate that Organogenesis Holdings Inc. will post -0.07 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Strs Ohio acquired a new position in Organogenesis during the first quarter valued at $105,000. Driehaus Capital Management LLC acquired a new position in shares of Organogenesis in the first quarter worth about $7,756,000. Trexquant Investment LP acquired a new position in shares of Organogenesis in the first quarter worth about $516,000. OMERS ADMINISTRATION Corp acquired a new position in shares of Organogenesis during the 1st quarter worth about $77,000. Finally, Ieq Capital LLC acquired a new position in shares of Organogenesis during the 1st quarter worth about $79,000. 49.57% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, Morgan Stanley lifted their price target on shares of Organogenesis from $4.00 to $6.00 and gave the stock an "equal weight" rating in a report on Wednesday, March 5th.

Organogenesis Company Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.